Charlene Banard, Former Global Head of Technical Operations Cell & Gene Therapy Strategy, Innovation Pipeline and PMO
Novartis
Novartis
Jeffrey Berkowitz, Board Member
H. Lundbeck A/S
H. Lundbeck A/S
Ron Cohen, M.D., President & CEO
Acorda Therapeutics
Acorda Therapeutics
Pamela Reilly Contag, Ph.D., Cofounder and CEO
BioEclipse Therapeutics
BioEclipse Therapeutics
Lisa Conte, founder, president, and CEO
Jaguar Health
Jaguar Health
John Crowley, Executive Chairman
Amicus Therapeutics
Amicus Therapeutics
Rich Daly, President
CARsgen Therapeutics
CARsgen Therapeutics
Raúl Díaz, Animal Health Large Molecules Biopharm. Operations
MSD, Montes Claros, MG, Brazil
MSD, Montes Claros, MG, Brazil
Tom Dilenge, Senior Partner for Global Public Policy, Regulatory and Governmental Strategy
Flagship Pioneering
Flagship Pioneering
Joseph Ferra, CFO
Elevation Oncology
Elevation Oncology
Anu Hans, VP, Strategic Initiatives
Janssen Supply Chain
Janssen Supply Chain
Fred Hassan, Managing Director
Warburg Pincus
Warburg Pincus
Paul Hastings, President and CEO
Nkarta Therapeutics
Nkarta Therapeutics
Axel Hoos, M.D., Ph.D., CEO
Scorpion Therapeutics
Scorpion Therapeutics
John Hubbard, Ph.D., Emeritus Editorial Advisory Board Member
Life Science Leader
Life Science Leader
Mitchell Katz, Ph.D., VSVP, Global Clinical Operations
Kyowa Kirin
Kyowa Kirin
Mary Rose Keller, VP, Head Of Clinical Operations
Acrivon Therapeutics
Acrivon Therapeutics
Jacks Lee, SVP Global Manufacturing and Supply
Merck
Merck
Martin Lehr, CEO
Context Therapeutics
Context Therapeutics
Sandy Macrae, Ph.D., President & CEO
Sangamo Therapeutics
Sangamo Therapeutics
Ken Moch, President
Euclidean Life Science Advisors, LLC
Euclidean Life Science Advisors, LLC
Sandra E. Poole, Chief Operating Officer
Mythic Therapeutics
Mythic Therapeutics
Dennis Purcell, Founder & Sr. Advisor
Aisling Capital
Aisling Capital
David Pyott, Board Member
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals
Paula Ragan, Cofounder, President and CEO
X4 Pharmaceuticals
X4 Pharmaceuticals
Chandra Ramanathan, Global Head of Innovation Hubs
Danaher Corporation
Danaher Corporation
Stephen Rapundalo, Ph.D., President & CEO
MichBio
MichBio
John Reynders, Ph.D., VP, R&D Strategy, Program Management, and Data Sciences
Alexion
Alexion
James Robinson, Emeritus Editorial Advisory Board Member
Life Science Leader
Life Science Leader
Tomasz Sablinski, M.D., Ph.D., Managing Director, Head of Clinical Development
Auven Therapeutics
Auven Therapeutics
Jim Scibetta, CEO
ImmuneID
ImmuneID
Chhaya Shah, SVP Technical Operations
Radius Health
Radius Health
Allan Shaw, Independent Consultant
Brandi Simpson, VP Business and Corporate Development
Voyager Therapeutics
Voyager Therapeutics
Andrew Skibo, Emeritus Editorial Advisory Board Member, Life Science Leader
MedImmune / AstraZeneca
MedImmune / AstraZeneca
Jason Urban, Ph.D., Sr. Dir. Quality Risk Management
Alexion
Alexion
Thomas Wiggans, Founder, CEO, Chairman
Dermira
Dermira
Leslie Williams, Cofounder, President and CEO hC Bioscience, Inc.
Tim Wright, CEO
MiMedx
MiMedx
ASK THE BOARD
- In September, You Testified Before Congress On The Inflation Reduction Act's (IRA) Real-World Impact On Rare Disease R&D And Small Molecule Therapies. Can You Summarize The Key Points?
- What New Technologies Offer The Most Promise For Improving Global Supply Chain Operations?
- How Can Leaders Balance Requests Of Employees To Continue Remote Working With The Need For Increased Business Efficiency And Achieving Strong Dynamics Among A Management Team?
- Given Drug Development Time Horizons, How Does A Company Best Navigate The Inevitable Vagaries Of Investor Therapeutic/Modality Sentiment And Its Collateral Consequences On Funding?
- What Impact Is The Inflation Reduction Act Already Having On Biopharma Companies, And What More Can The Industry Do Going Forward?
- How Can Executives Work Through Tightened Budgets And Manage Tradeoffs While Keeping The Workforce Happy And Motivated?
IN THIS MONTH'S ISSUE
- Gene Editing Versus Gene Therapy: Is There A Difference?
- The Ozempic Dilemma: What Makes A Dual Brand Approach Viable?
- Ensuring Diversity And Accessibility In Neurological Research
- A New Year's Resolution Suggestion For The FDA
- Pharma's Customer Engagement Evolution: Is Your Data Governance Keeping Pace?
@LIFESCILEADER1
This website uses cookies to ensure you get the best experience on our website. Learn more